009420 — Hanall Biopharma Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapHigh Flyer

Annual cashflow statement for Hanall Biopharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	19,764	8,896	251	3,509	-1,805
Depreciation
Amortisation
Non-Cash Items	-8,496	4,929	6,425	2,877	4,870
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-13,233	-15,710	15,475	20,010	3,174
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	929	840	25,204	29,643	9,360
Capital Expenditures	-7,390	-9,002	-7,677	-9,198	-23,068
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	5,072	17,032	-2,915	-2,690	-4,425
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-2,318	8,030	-10,592	-11,887	-27,493
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-519	-307	-10,644	-814	760
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-1,920	8,594	4,047	16,882	-17,336